[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mindwalk Holdings Corp (HYFT)

Mindwalk Holdings Corp (HYFT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,620
  • Shares Outstanding, K 46,157
  • Annual Sales, $ 17,590 K
  • Annual Income, $ -21,690 K
  • EBIT $ -9 M
  • EBITDA $ -5 M
  • 60-Month Beta 0.79
  • Price/Sales 3.49
  • Price/Cash Flow N/A
  • Price/Book 6.59

Options Overview Details

View History
  • Implied Volatility 172.55% (-2.85%)
  • Historical Volatility 105.72%
  • IV Percentile 43%
  • IV Rank 14.39%
  • IV High 494.40% on 02/09/26
  • IV Low 118.45% on 12/05/25
  • Expected Move (DTE 27) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 105
  • Volume Avg (30-Day) 203
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 3,386
  • Open Int (30-Day) 2,497
  • Expected Range 1.5300 to 1.5300

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 1
  • High Estimate $-0.05
  • Low Estimate $-0.05
  • Prior Year $-0.04
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +25.41%
on 05/19/26
1.9850 -22.92%
on 06/02/26
+0.2700 (+21.43%)
since 05/18/26
3-Month
0.9900 +54.55%
on 03/30/26
1.9850 -22.92%
on 06/02/26
+0.3700 (+31.90%)
since 03/18/26
52-Week
0.8200 +86.59%
on 06/24/25
3.2459 -52.86%
on 08/25/25
+0.5200 (+51.49%)
since 06/18/25

Most Recent Stories

More News
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones,...

ABSI : 7.41 (+3.20%)
HYFT : 1.5300 (+2.00%)
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery

ReefIQ turns fragmented biological data into governed, queryable context for AI-enabled drug discovery and biologics development.

HYFT : 1.5300 (+2.00%)
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns

HYFT® technology computationally identified and prioritized a pan-serotype dengue target before immunization. Preclinical data support the prediction at the binding level: immunization with immunogens...

HYFT : 1.5300 (+2.00%)
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-Specific Coverage

MindWalk Holdings Corp. (NASDAQ: HYFT), a bio-native AI therapeutic research and technology company, today announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's...

HYFT : 1.5300 (+2.00%)
The Biology Came First.

Over 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth...

CGEM : 15.03 (+4.09%)
IDXX : 562.09 (+2.93%)
IPA : 2.07 (+7.25%)
ARGX : 877.72 (-1.63%)
XNCR : 12.64 (-1.10%)
HYFT : 1.5300 (+2.00%)
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results

Third Consecutive Quarter of Year-Over-Year Revenue Growth | First Annual Enterprise LensAI™ Platform Contract | Launch of B cell Llama™ Nanobody Discovery Platform

HYFT : 1.5300 (+2.00%)
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era

Peer-reviewed study in ACS Biomacromolecules demonstrates modular VHH potency, cross-variant therapeutic activity, and a newly described immune-priming mechanism; MindWalk holds first right to commercialize...

HYFT : 1.5300 (+2.00%)
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

The Company to host an earnings conference call via webcast

HYFT : 1.5300 (+2.00%)
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced an application of its proprietary HYFT ®...

HYFT : 1.5300 (+2.00%)
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

MindWalk Holdings Corp. (“MindWalk” or the “Company”) (Nasdaq: HYFT) today announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic...

HYFT : 1.5300 (+2.00%)

Business Summary

MindWalk is a Bio-Native AI company transforming drug discovery and development. MindWalk, formerly known as ImmunoPrecise Antibodies Ltd., is based in AUSTIN, Texas.

See More

Key Turning Points

3rd Resistance Point 1.6267
2nd Resistance Point 1.5833
1st Resistance Point 1.5567
Last Price 1.5300
1st Support Level 1.4867
2nd Support Level 1.4433
3rd Support Level 1.4167

See More

52-Week High 3.2459
Fibonacci 61.8% 2.3192
Fibonacci 50% 2.0329
Fibonacci 38.2% 1.7467
Last Price 1.5300
52-Week Low 0.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.